Iptacopan for hard-to-treat autoimmune hemolytic anemia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug, iptacopan, for people with autoimmune hemolytic anemia (AIHA) that hasn't responded well to steroids. The goal is to see if it can help raise your red blood cell counts and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with autoimmune hemolytic anemia (AIHA) that is not caused by another condition like lupus or rheumatoid arthritis
- Your hemoglobin (a part of your red blood cells) is below 100 g/L (or 10 g/dL) right now
- You have tried steroids (like prednisone) for AIHA and they didn't work, you needed a high dose to keep your blood counts up, or you couldn't take them
- You are willing to get or have already received vaccines for meningitis and pneumonia, or take antibiotics to prevent infection
- You are not pregnant, breastfeeding, or have an active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment (Inaticabtagene Autoleucel, a type of CAR-T cell therapy) for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved after at least three prior treatments. The goal is to see if it can help control the disease.
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Hear when a new AIHA - Warm Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.